Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

Investors eye Shell, Maersk, Novo Nordisk, Ferrari, BMW, Unicredit, and HSBC earnings this week. In this article Taken from ...

Hims is expanding beyond telehealth with a push into hormone care, while building out at-home testing and virtual care services. ・Peptides is also seen as the next growth driver, with Bank of America ...

The Food and Drug Administration has proposed removing popular weight loss drugs such as Ozempic and Wegovy from a key ...

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an ...

Novo Nordisk will launch its oral Ozempic pill for type 2 diabetes in the U.S. next week, offering competitive pricing and ...

Novo Nordisk says an oral semaglutide may help children and teens with Type 2 diabetes, with experts weighing benefits and ...

Novo Nordisk, which makes the GLP-1 semaglutide medications Ozempic and Wegovy, announced that it’s rolling out an “Ozempic ...

Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, surged 50% on Friday after raising $301.5 million in an upsized US initial public offering that priced at the top of a ...

The ​Canadian ‌health regulator said on Friday ‌that ​it ⁠had approved ⁠Canada-based Apotex's generic version of ​semaglutide ...

Korrie Stevenson had been feeling off for months. She would look at a gorgeous birthday cake or walk outside to a ...

The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.